Event moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, July 8, 2021, 5:00 PM – 6:00 PM ET

 

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Regeneron Pharmaceuticals Inc and Sanofi Genzyme, and Takeda Oncology.

Topics to Be Discussed

• Overview of non-small-cell lung cancer (NSCLC) incidence and prognosis, patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting patient care
• Management of localized and metastatic NSCLC in patients who harbor actionable molecular alterations (eg, EGFR, ALK, HER2, RET and MET exon 14 skipping mutations): Approach to mutation testing, efficacy and tolerability of available agents and management of toxicities
• Management of metastatic NSCLC without actionable mutations: Assessment and relevance of PD-L1 status, mechanisms of action of immune checkpoint inhibitors (ICIs), and efficacy and tolerability of ICIs alone or combined with other agents
• Identification, incidence and management of ICI-associated immune-related adverse events; use of and contraindications for ICIs in special populations (eg, patients with autoimmune disorders)
• Newly approved agents: Mechanism of action, efficacy, and incidence, type and management of associated adverse events

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Acknowledge available Phase III findings supporting the use of adjuvant osimertinib for patients with early-stage non-small cell lung cancer (NSCLC) with EGFR mutations, and consider the potential effects of this information on current and future clinical practice.
• Analyze the biologic basis for the investigation of immune checkpoint inhibitors for nonmetastatic NSCLC, and evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies as a component of neoadjuvant or adjuvant therapy.
• Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied outside of a research setting.
• Assess the efficacy and safety of commercially available ALK inhibitors for patients with metastatic NSCLC and an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs as first- and later-line therapy.
• Recall published and emerging data with commercially available and experimental agents exploiting other oncogenic pathways (ie, ROS1, RET, MET, HER2) mediating the pathogenesis of tumors in unique patient subsets.
• Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
• Appreciate the recent FDA approvals of nivolumab in combination with ipilimumab with and without chemotherapy as first-line treatment for metastatic NSCLC, and appropriately incorporate these novel regimens into clinical care.
• Recognize common side effects associated with novel systemic agents in the treatment of NSCLC, and implement supportive management strategies to minimize and ameliorate these toxicities.
• Recall the design of ongoing clinical trials evaluating novel agents and strategies in NSCLC, and counsel appropriate patients about availability and participation.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.researchtopractice.com/Webinars/ONS2021/MTP/NSCLC/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Plues has no relevant conflicts of interest to disclose. The following faculty (and their spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Piotrowska – Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medtronic Inc, Takeda Oncology; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Spectrum Pharmaceuticals Inc, Takeda Oncology, Tesaro, A GSK Company.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Regeneron Pharmaceuticals Inc and Sanofi Genzyme, and Takeda Oncology.